PeerLINC concluded a three-day online training on new regimens for drug-resistant tuberculosis and other special TB topics. Participants included National TB Program (NTP) managers across Mongolia. Knowledge areas covered included updates to WHO-recommended regimens, including BPaL/M, managing adverse drug reactions, DR-TB in pregnancy, TB-diabetes comorbidity, and modified regimens for drug-susceptible TB in special cases.

PeerLINC recently welcomed a delegation from Bangladesh’s National Tuberculosis Program (NTP) to a weeklong capacity-building program aimed at accelerating the country’s transition to shorter, safer treatment regimens for drug-resistant tuberculosis (DR-TB). The training combined interactive lectures, workshops, and field visits across Metro Manila to offer a comprehensive view of implementing the WHO-recommended six-month BPaLM/BPaL regimens.

The Global Technical Expert Council (GTEC), an has announced a significant expansion, welcoming 22 new members from several additional countries.

In a significant step toward improving drug-resistant tuberculosis (DR-TB) care, the PeerLINC Knowledge Hub conducted an intensive training from February 3-7, 2025, equipping national and regional personnel of Disease Prevention and Control Bureau (DPCB) of DOH of the Philippines with the knowledge and skills to implement the BPaL/M treatment regimen.

In PeerLINC’s first year of operations it empowered eight countries to accelerate the adoption of shorter, safer, and more effective DR-TB treatments, improving lives and strengthening healthcare systems worldwide.

PeerLINC has launched the Global Technical Expert Council (G-TEC), a global network of leading TB experts providing scientific, clinical, and programmatic guidance to support national TB programs and optimize drug-resistant TB care worldwide.

In February 2024, Peru became one of the first in the region to adopt the BPaLM (bedaquiline, pretomanid, linezolid, and moxifloxacin) regimen, recommended by the World Health Organization (WHO) for the treatment of drug-resistant tuberculosis. To date, 790 patients have received this regimen, while a total of 1,231 people have benefited from shortened oral treatments, achieving a better quality of life and increasing the therapeutic success rate.

A faster and vastly more effective treatment for drug-resistant tuberculosis is being rolled out in the Asia-Pacific region, raising hopes of a "new era" in tackling one of the world's deadliest infectious diseases.